
Clearpoint Neuro Inc
CLPTNASDAQ NMS - GLOBAL MARKETKey Statistics
Open
$13.08
Day High
$13.36
Day Low
$12.01
Prev. Close
$12.24
VolumeShares traded today.
1.48M
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$379.97M
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-12.58
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$30.10
52W LowLowest price over the past 52 weeks.
$8.27
50D MAAverage closing price over the last 50 trading days.
$10.70
200D MAAverage closing price over the last 200 trading days.
$14.14
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
+8.3%1M
+22.5%6M
-13.2%YTD
-9.7%1Y
+7.3%About
Paul Bottomley is an American, English and Australian medical physicist. He pioneered the development of magnetic resonance imaging (MRI) that lead to modern commercial clinical 1.5 tesla MRI scanners, along with methods for performing noninvasive localized magnetic resonance spectroscopy (MRS) and applying them to the study of energy supply in human heart disease. In 2022 he retired as Russell H. Morgan Professor of Radiology and Director of the Division of MR Research at Johns Hopkins University where he is currently Professor Emeritus. He has about 200 peer-reviewed journal articles, over 50 U.S patents in MRI, MRS, and MRI-safe implantable lead technologies. He was a Founder and past member of the Board of Directors of SurgiVision Inc, a 1998 Johns Hopkins University start-up company which became MRI Interventions Inc, and is currently known as ClearPoint Neuro Inc.
www.clearpointneuro.com/Company Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade CLPT
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.